Clinical Trial Diversity: We Must ‘Turn This Moment Into A Movement’
Executive Summary
Pfizer and Genentech execs describe steps they’ve taken to increase diversity in clinical trials from moving trial sites into new neighborhoods to modifying protocols and holding others accountable for diversity.
You may also be interested in...
Clinical Trial Diversity Efforts Look Beyond COVID-19
At The Atlantic’s Health Equity Summit, panel discussions highlighted efforts to improve diversity in clinical trials of diseases like lupus, which disproportionately affects women of color.
NCI’s Clinical Trial Accrual Is ‘Better’ Than Pharma Industry’s, Director Sharpless Says
NCI networks had vast under accrual in the past year, but Sharpless says industry has been affected to a greater degree. He says the institute also has been better at accruing minority patients.
Clinical Trial Diversity Requires Community-Based Research Infrastructure, US FDA’s Woodcock Says
COVID-19 trials could have reached underserved populations better if research infrastructure was in place where people routinely get their health care, acting commissioner Janet Woodcock says; PhRMA is looking to establish a public-private partnership that would build a sustainable community-based infrastructure for clinical research.